Ratings Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18/06/2025			5-day change	1st Jan Change
162,300.00 ^KRW	+0.31%		+0.06%	-9.98%

08:20am	Celltrion Healthcare UK Limited Opens New UK Headquarters in Uxbridge, UK	CI
06-16	Celltrion, Inc. Announces U.S. FDA Approval of Additional Presentation of Steelara®? (Ustekinumab-Stba)	CI

Summary: Celltrion, Inc.

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Highlights: Celltrion, Inc.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Celltrion, Inc.

With an expected P/E ratio at 41.85 and 29.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The company's earnings releases usually do not meet expectations.

Ratings Chart: Celltrion, Inc.

Source: Surperformance

ESG chart: Celltrion, Inc.

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	CELLTRION, INC.				26.19B
	LONZA GROUP AG				48.38B
	BEONE MEDICINES LTD.				32.21B
	IQVIA HOLDINGS INC.				26.75B
	EUROFINS SCIENTIFIC SE				12.52B
	ICON PUBLIC LIMITED COMPANY				11.41B
	QIAGEN N.V.				10.08B
	Average				23.93B
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

BBB

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes